Cargando…

Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis

Despite the usefulness of traditional Chinese medicine (TCM) in the treatment of lower deep vein thrombosis (DVT), there is no consensus on safety and efficacy. We aim to systematically evaluate the safety and efficacy of TCM combined with Rivaroxaban in the treatment of lower limb DVT. METHODS: An...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Dandan, Qi, Gui, Adu, Isaac Kumi, Wu, Haichao, Zhu, Mingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524882/
https://www.ncbi.nlm.nih.gov/pubmed/36181038
http://dx.doi.org/10.1097/MD.0000000000029483
_version_ 1784800586619682816
author Zheng, Dandan
Qi, Gui
Adu, Isaac Kumi
Wu, Haichao
Zhu, Mingyuan
author_facet Zheng, Dandan
Qi, Gui
Adu, Isaac Kumi
Wu, Haichao
Zhu, Mingyuan
author_sort Zheng, Dandan
collection PubMed
description Despite the usefulness of traditional Chinese medicine (TCM) in the treatment of lower deep vein thrombosis (DVT), there is no consensus on safety and efficacy. We aim to systematically evaluate the safety and efficacy of TCM combined with Rivaroxaban in the treatment of lower limb DVT. METHODS: An online search of databases such as Cochrane Library, Embase, Pubmed, and Web of science, as well as CBM, China Science and Technology Journal Database, China Knowledge Network (CNKI) and Wanfang Data (from inception to July, 2021) was performed. All published clinical randomized controlled trials (RCTs) were screened manually, evaluated for quality and considered for meta-analysis using RevMan 5.3. RESULTS: Nine RCTs with a total of 730 cases were included, 368 cases in the trial group were treated with TCM combined with Rivaroxaban, and 362 cases in the control group were treated with Rivaroxaban alone after surgery. Clinical efficiency was significantly higher in the test group [OR = 3.33, 95% CI (2.01, 5.53), P < .00001], the circumference of the affected limb was significantly lower in the thigh and calf, respectively [MD = −1.48, 95% CI (−1.88, −1.09), P < .00001], [MD = −0.54, 95% CI (−0.62, −0.46), P < .00001], pain scores were significantly lower [MD = −0.97, 95% CI (−1.58, −0.36), P = .002], coagulation index plasma fibrinogen (FIB) was significantly lower [MD = −0.85, 95% CI (−1.18, −0.52), P < .00001], coagulation function index D-2 aggregates were significantly reduced [MD = −0.69, 95% CI (−1.13, −0.24), P = .002], serum hypersensitive C-reactive protein (hs-CRP) measurements were significantly reduced [MD = −5.37, 95% CI (−9.20, −1.55), P = .006], complications measurement was significantly lower [OR = 0.60, 95% CI (0.27, 1.30), P = .20], activated partial thrombin time (ATPP) measurement was significantly lower [MD = 5.70, 95% CI (4.28, 7.12), P < .00001] and prothrombin time (PT) measurement was significantly lower [MD = 1.64, 95% CI (0.70, 2.57), P = .0006]. CONCLUSION: Based on the available evidence, TCM combined with Rivaroxaban for treating lower extremity DVT have better clinical efficacy and safety profile, reducing the risk of bleeding complications and adverse effects. Further improved studies are needed to support this inference.
format Online
Article
Text
id pubmed-9524882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95248822022-10-03 Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis Zheng, Dandan Qi, Gui Adu, Isaac Kumi Wu, Haichao Zhu, Mingyuan Medicine (Baltimore) Research Article Despite the usefulness of traditional Chinese medicine (TCM) in the treatment of lower deep vein thrombosis (DVT), there is no consensus on safety and efficacy. We aim to systematically evaluate the safety and efficacy of TCM combined with Rivaroxaban in the treatment of lower limb DVT. METHODS: An online search of databases such as Cochrane Library, Embase, Pubmed, and Web of science, as well as CBM, China Science and Technology Journal Database, China Knowledge Network (CNKI) and Wanfang Data (from inception to July, 2021) was performed. All published clinical randomized controlled trials (RCTs) were screened manually, evaluated for quality and considered for meta-analysis using RevMan 5.3. RESULTS: Nine RCTs with a total of 730 cases were included, 368 cases in the trial group were treated with TCM combined with Rivaroxaban, and 362 cases in the control group were treated with Rivaroxaban alone after surgery. Clinical efficiency was significantly higher in the test group [OR = 3.33, 95% CI (2.01, 5.53), P < .00001], the circumference of the affected limb was significantly lower in the thigh and calf, respectively [MD = −1.48, 95% CI (−1.88, −1.09), P < .00001], [MD = −0.54, 95% CI (−0.62, −0.46), P < .00001], pain scores were significantly lower [MD = −0.97, 95% CI (−1.58, −0.36), P = .002], coagulation index plasma fibrinogen (FIB) was significantly lower [MD = −0.85, 95% CI (−1.18, −0.52), P < .00001], coagulation function index D-2 aggregates were significantly reduced [MD = −0.69, 95% CI (−1.13, −0.24), P = .002], serum hypersensitive C-reactive protein (hs-CRP) measurements were significantly reduced [MD = −5.37, 95% CI (−9.20, −1.55), P = .006], complications measurement was significantly lower [OR = 0.60, 95% CI (0.27, 1.30), P = .20], activated partial thrombin time (ATPP) measurement was significantly lower [MD = 5.70, 95% CI (4.28, 7.12), P < .00001] and prothrombin time (PT) measurement was significantly lower [MD = 1.64, 95% CI (0.70, 2.57), P = .0006]. CONCLUSION: Based on the available evidence, TCM combined with Rivaroxaban for treating lower extremity DVT have better clinical efficacy and safety profile, reducing the risk of bleeding complications and adverse effects. Further improved studies are needed to support this inference. Lippincott Williams & Wilkins 2022-09-30 /pmc/articles/PMC9524882/ /pubmed/36181038 http://dx.doi.org/10.1097/MD.0000000000029483 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle Research Article
Zheng, Dandan
Qi, Gui
Adu, Isaac Kumi
Wu, Haichao
Zhu, Mingyuan
Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title_full Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title_fullStr Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title_full_unstemmed Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title_short Efficacy of traditional Chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: A meta-analysis
title_sort efficacy of traditional chinese medicine combined with rivaroxaban in the treatment of lower extremity deep vein thrombosis: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524882/
https://www.ncbi.nlm.nih.gov/pubmed/36181038
http://dx.doi.org/10.1097/MD.0000000000029483
work_keys_str_mv AT zhengdandan efficacyoftraditionalchinesemedicinecombinedwithrivaroxabaninthetreatmentoflowerextremitydeepveinthrombosisametaanalysis
AT qigui efficacyoftraditionalchinesemedicinecombinedwithrivaroxabaninthetreatmentoflowerextremitydeepveinthrombosisametaanalysis
AT aduisaackumi efficacyoftraditionalchinesemedicinecombinedwithrivaroxabaninthetreatmentoflowerextremitydeepveinthrombosisametaanalysis
AT wuhaichao efficacyoftraditionalchinesemedicinecombinedwithrivaroxabaninthetreatmentoflowerextremitydeepveinthrombosisametaanalysis
AT zhumingyuan efficacyoftraditionalchinesemedicinecombinedwithrivaroxabaninthetreatmentoflowerextremitydeepveinthrombosisametaanalysis